Lung Cancer Trial Results
Enhertu Extends Progression-Free Survival for Advanced Lung Cancer Patients in Trial
Anonymous
Key Points
1
DESTINY-Lung04 enrolled 454 patients with advanced, non-squamous lung cancer carrying HER2 mutations. Enhertu is an antibody-drug conjugate designed to deliver a chemotherapy payload directly to cancer cells expressing HER2, while the comparator was platinum-based chemotherapy plus pembrolizumab (Keytruda).
2
The companies said Enhertu is the first HER2-directed medicine to outperform the global standard of care in a phase 3 trial for this setting, moving the drug from use after prior treatment into the first-line setting.
3
Patients receiving Enhertu had longer durability of response and a favorable trend in time to second disease progression, extending benefits beyond the initial progression-free-survival result.
4
AstraZeneca and Daiichi Sankyo executives emphasized the potential value of treating patients at metastatic diagnosis, when delaying disease progression may have the greatest opportunity to improve outcomes. AstraZeneca oncology executive Susan Galbraith called the findings evidence for Enhertu’s potential role at the time of metastatic diagnosis.
5
Enhertu generated roughly $5 billion in combined fiscal 2025 sales for AstraZeneca and Daiichi Sankyo, with revenue driven overwhelmingly by breast-cancer indications, underscoring why the lung-cancer expansion is clinically important but commercially incremental.
Enhertu, a targeted cancer drug from AstraZeneca and Daiichi Sankyo, significantly extended survival in patients with advanced lung cancer carrying HER2 mutations. In the phase 3 DESTINY-Lung04 trial, the drug delayed disease progression to 14.3 months versus 8.3 months with standard chemotherapy and immunotherapy Source 1, cutting the risk of progression or death by 37%. The results mark the first time a HER2-targeted drug has beaten the global standard of care as a first-line lung cancer treatment.
Despite this clinical win, the commercial opportunity remains modest. Enhertu generated roughly $5 billion in combined 2025 sales, driven almost entirely by breast cancer uses Source 1. The lung cancer population—about 2% to 4% of all lung cancer patients with HER2 mutations—is small and underserved, meaning the drug's total revenue may grow slowly even with this new approval path.
HER2 Mutations Open a Rare Lung Cancer Niche
The DESTINY-Lung04 trial enrolled 454 patients with advanced, non-squamous lung cancer carrying mutations in the HER2 gene Source 1. Enhertu is an antibody-drug conjugate—a precision weapon that attaches chemotherapy directly to cancer cells expressing HER2, minimizing damage to healthy tissue. Patients on Enhertu achieved a 70% response rate, meaning tumors shrank or disappeared in seven of ten patients, versus just 45% with platinum-based chemotherapy plus pembrolizumab (Keytruda) Source 1.
Treatment Durability and Disease Control Benefits
Beyond the initial progression-free survival advantage, Enhertu showed lasting benefits. Patients receiving Enhertu had longer-lasting responses—tumors stayed shrunk longer—and a favorable trend in time to second disease progression Source 1. This means the drug is doing more than just delaying the first sign of cancer return; it's extending the window of disease control. AstraZeneca oncology executive Susan Galbraith emphasized that treating patients at metastatic diagnosis offers the greatest opportunity to improve outcomes Source 1.
Serious Side Effects Demand Close Monitoring
Enhertu's safety profile raised concerns. Interstitial lung disease or pneumonitis—inflammation of lung tissue—occurred in 20.8% of patients receiving Enhertu, and four patients died from these complications Source 1. Severe treatment-related adverse events were overall similar between the Enhertu and chemotherapy groups, but the lung toxicity signal requires careful patient selection and ongoing monitoring during treatment.
Limited Commercial Expansion Despite Clinical Victory
Enhertu is already approved for breast cancer, where it drives nearly all current sales Source 1. The lung cancer indication is clinically important for a neglected population but commercially incremental because HER2-mutant lung cancer affects only 2% to 4% of lung cancer patients Source 1. Overall survival data remain immature, and differences in follow-up treatments make early comparisons difficult to interpret. Still, the trial supports Enhertu's potential as a first-line option for this rare molecular subtype.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
18
Articles
47
Reach
65
A
AnonymousAuthor
